Biomaterials boosted as investors return / This biotech stock is a buy thanks to its cancer treatment pipeline, Citi says / Leerink upgrades this beaten-down biotech stock, says investors should buy the dip / Buy this biotech stock that can rally more than 65%, Goldman says / This little-known biotech stock is a buy that's primed to double in price, Goldman says